Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC
The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …
considerable potential to improve clinical outcomes across multiple cancer types, including …
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
DA Fennell, Y Summers, J Cadranel, T Benepal… - Cancer treatment …, 2016 - Elsevier
The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …
[HTML][HTML] Benchmarking of Nanopore R10. 4 and R9. 4.1 flow cells in single-cell whole-genome amplification and whole-genome shotgun sequencing
Third-generation sequencing can be used in human cancer genomics and epigenomic
research. Oxford Nanopore Technologies (ONT) recently released R10. 4 flow cell, which …
research. Oxford Nanopore Technologies (ONT) recently released R10. 4 flow cell, which …
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing …
SM Lee, C Schulz, K Prabhash, D Kowalski… - The Lancet, 2023 - thelancet.com
Background Despite immunotherapy advancements for patients with advanced or metastatic
non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an …
non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an …
Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09)
JH Cho, SH Lim, HJ An, KH Kim, KU Park… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Approximately 10% of patients with epidermal growth factor receptor (EGFR)
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd, L Bazhenova… - The lancet …, 2016 - thelancet.com
Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic …
Background The molecular profiling of patients with advanced non-small-cell lung cancer
(NSCLC) for known oncogenic drivers is recommended during routine care. Nationally …
(NSCLC) for known oncogenic drivers is recommended during routine care. Nationally …
Osimertinib in pretreated T790M-positive advanced non–small-cell lung cancer: AURA study phase II extension component
JCH Yang, MJ Ahn, DW Kim… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing (EGFR m) and T790M …
kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing (EGFR m) and T790M …
Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non–small-cell lung cancer
R Govindan, A Szczesna, MJ Ahn… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Patients with squamous non–small-cell lung cancer (NSCLC) have poor prognosis
and limited treatment options. This randomized, double-blind, phase III study investigated …
and limited treatment options. This randomized, double-blind, phase III study investigated …
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled …
Background There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …